Assessing the effects of radiotherapy on tumors in cervical and pancreatic cancer
Official title: MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)
Run by Washington University School of Medicine · NCT05975593 · Data updated 2026-11-12
This study is testing how radiotherapy affects tumors in patients with locally advanced cervical and pancreatic cancer by collecting samples and using special imaging before, during, and after treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Status | Recruiting |
| Started | January 11, 2024 |
| Main results expected | December 31, 2032 |
| Study ends | December 31, 2032 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT05975593 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been confirmed to receive radiotherapy for locally advanced cervical or pancreatic cancer.
✕Probably not a fit
Patients with medical or anatomical issues that prevent safe acquisition of biospecimens may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study is a prospective longitudinal assessment aimed at capturing biospecimens and treatment-related data from patients undergoing definitive-intent chemoradiotherapy for locally advanced cervical and pancreatic cancer. It involves collecting tumor biopsies, blood samples, and utilizing diffusion basis spectrum imaging (DBSI) MRI to evaluate the tumor microenvironment before, during, and after treatment. The study is designed to adapt dynamically based on the data collected, providing a comprehensive understanding of the effects of radiotherapy on these cancers.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients with locally advanced cervical and pancreatic cancers.
How similar studies have gone: Other studies have shown success in utilizing similar approaches to assess treatment effects in cancer, indicating potential for meaningful insights from this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmation of intent to receive radiotherapy for one of the following diagnoses: * Cervical cancer * Pancreatic cancer * ECOG performance status ≤ 2 * At least 18 years old * Able to understand and willing to sign an IRB-approved written informed consent document Exclusion Criteria: * Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician
Where it's running
-
Washington University School of Medicine
St Louis, Missouri, United States Recruiting
Study contacts
- Principal investigator: Michael Waters, M.D., Ph.D. — Washington University School of Medicine
- Study coordinator: Michael Waters, M.D., Ph.D.
- Email: m.r.waters@wustl.edu
- Phone: 314-273-0275
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining SBRT with defactinib and avutometinib for advanced pancreatic cancer
This Phase 2 trial tests whether adding the targeted drugs defactinib and avutometinib to adaptive SBRT helps people with locally advanced or borderline resectable pancreatic cancer stay progression-free longer than SBRT alone.
-
MRI scan for detecting pancreatic cancer in people at high risk
This study tests a dedicated pancreas MRI (MRP) tool to see if it helps find pancreatic cancer earlier in people with a strong family or genetic risk.
-
CAIX-targeted 18F-T2 PET/CT imaging in solid tumors
This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.
-
Carbon nanoparticle‑loaded iron for advanced solid tumors
This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.
-
Chemotherapy With IMD10 (Focused Ultrasound) for Borderline Resectable or Locally Advanced Pancreatic Cancer
This trial tests whether adding IMD10 focused ultrasound to a standard chemotherapy regimen helps people with borderline resectable or locally advanced pancreatic cancer see better survival.
-
Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors
This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.